Robust Growth: JB Chemicals & Pharmaceuticals' Stellar Performance

JB Chemicals & Pharmaceuticals reported a 22% YoY increase in net profit for the December quarter. The profit was driven by a favourable product mix and operational efficiencies, with revenue rising to Rs 1,065 crore. CEO Nikhil Chopra emphasized the company's strategic priorities and future growth plans.

JB Chemicals & Pharmaceuticals reported a strong 22% year-on-year increase in net profit, reaching Rs 198 crore for the December quarter. This growth was driven by an advantageous product mix and enhanced operational efficiencies.

The company's revenue for the October-December period rose to Rs 1,065 crore, up from Rs 963 crore the previous year, as detailed in their recent statement. CEO and Whole-Time Director Nikhil Chopra credited the company's domestic formulations business, which outpaced the Indian pharmaceutical market, with contributing significantly to this success.

Chopra highlighted ongoing momentum in both the CDMO and international formulations businesses, contributing to robust growth in key markets. With a strong balance sheet and sustained cash flow generation, JB Pharma aims to continue delivering profitable growth by strengthening its flagship brands, accelerating growth in chronic therapies, and scaling its CDMO operations.

(With inputs from agencies.)